Leprosy Treatment Guidelines

Medication Regimens

The World Health Organization recommends clofazimine dosage of 50-100 mg daily for multibacillary leprosy, with anti-inflammatory and antimycobacterial properties 1, 2
The Centers for Disease Control and Prevention suggests dapsone monitoring, including complete blood count and liver function tests, due to adverse effects such as hemolytic anemia and methemoglobinemia 3
The American Thoracic Society notes that clofazimine comes in 50 and 100 mg gelcaps that cannot be split, and has adverse effects including skin pigmentation, ichthyosis, gastrointestinal intolerance, and QT interval prolongation 1, 2

The Infectious Diseases Society of America recommends that treatment should be continued during pregnancy as benefits outweigh risks, with close monitoring required 4
The American Academy of Pediatrics suggests that clofazimine has been well-tolerated in pediatric leprosy trials, with a dosage of 1-2 mg/kg/day (maximum 100 mg) 1

The National Institutes of Health recommends clinical monitoring for treatment response, with lesion flattening expected by 4-6 weeks after treatment initiation, and post-treatment surveillance to monitor for signs of relapse 4
The Centers for Disease Control and Prevention suggests monitoring for drug toxicity, including regular assessment of liver function and complete blood count 3
The American Heart Association notes that QT interval monitoring with ECG is necessary when using clofazimine, especially when combined with other QT-prolonging medications 2

The World Health Organization recommends screening for G6PD deficiency before treatment with Dapsone due to the risk of hemolytic anemia and methemoglobinemia 5
Dapsone can cause side effects such as hemolysis, methemoglobinemia, nausea, and vomiting, and requires regular monitoring of complete blood count and liver function tests 5

The World Health Organization recommends dosing clofazimine at 50-100 mg daily with meals or milk to maximize absorption and reduce gastrointestinal effects, with a warning about pink to brownish-black skin discoloration occurring in 75-100% of patients within 1-4 weeks, which resolves 6-12 months after stopping 6
Baseline ECG and monitoring of QT interval at 2 weeks and after adding any QT-prolonging medications is necessary when administering clofazimine, available as 100 mg capsules that cannot be split 6

Distinguish leprosy reactions (type 1 reversal reactions, type 2 erythema nodosum leprosum) from treatment failure—reactions require anti-inflammatory management but continuation of MDT, as stated by the European League Against Rheumatism 7

The World Health Organization recommends fixed-dose regimens for leprosy treatment in adults, which differs from weight-based dosing used in other infections, such as leishmaniasis where miltefosine uses 2.5 mg/kg/day 8, 9

The fixed-dose approach in leprosy reflects simplified field implementation, proven efficacy, and logistical advantages, with fixed-dose MDT regimens demonstrating effectiveness across diverse patient populations without relapse over long-term follow-up 8, 9